N/A
Completed N=241,981
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
Source: ClinicalTrials.gov NCT05073692 ↗Enrolled (actual)
241,981
Serious AEs
—
Results posted
Nov 2025
Primary outcomePrimary: Incidence of 3-point Major Adverse Cardiovascular Events (MACE) — 11,348; 393; 424; 296 Participants
Summary
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of 3-point Major Adverse Cardiovascular Events (MACE) |
11,348; 393; 424; 296 | — |
Eligibility Criteria
- Dispensing of either of the set of drugs being compared
- No prior dispensing of nor contraindication for any of the drugs compared
- Evidence of Type 2 Diabetes Mellitus diagnosis
- Age 18 or older
- Not currently pregnant
- No evidence of dementia or short-term life expectancy from prior cancer diagnoses
- History of ≥2 years of continuous health plan membership
- ≥1 A1c test in the past 18 months
Data sourced from ClinicalTrials.gov (NCT05073692). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.